8-K filing — Celcuity Inc. (CELC)
Filed: 2026-08-26 AccNo: 0001193125-26-365975 Size: 406 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Stifel Maintains Buy on Celcuity, Lowers Price Target to $150
Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $175 to $150.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug
Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $165 to $175.
Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target
Citizens analyst Silvan Turkcan reiterates Celcuity (NASDAQ:CELC) with a Market Outperform and maintains $177 price target.